Trial reportBrain imaging and behavior2025
Effect of a single dose of lorazepam on resting state functional connectivity in healthy adults.
Trial report in Brain imaging and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical-State Validation Should Precede Patient-Level Use of Glioma Connectivity Anomaly Maps.NMR in biomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lorazepam is a fast-acting benzodiazepine that is widely used to manage anxiety symptoms through modulation of GABAergic activity. Despite being one of the most prescribed benzodiazepines, the effects of a single dose of lorazepam on brain functional connectivity at rest is not known. In this placebo-controlled, crossover study, twenty healthy adult participants (9 women; 26.2 ± 5.2 years) underwent two resting-state fMRI (rs-fMRI) scans following administration of either lorazepam (2.5 mg) or placebo. Imaging data were analyzed using an individual brain network parcellation approach and differences in functional connectivity among 78 individual-specific ROIs were estimated. Compared to placebo, functional connectivity was reduced following administration of lorazepam between the left medial paracentral lobule and left temporal pole and between the left posterior cingulate sulcus and right cuneus. Reduced connectivity within higher-order cognitive networks partly supports what has been reported for other benzodiazepines such as midazolam and alprazolam. However, differences across benzodiazepines - possibly due to pharmacokinetics, dosage and receptor selectivity - underscore the need for further research.
Indexed as
Identifiers
40646404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.